Immune-Boosting drug trial offers new hope to slow devastating ALS
NCT ID NCT03039673
Summary
This study tested whether a low-dose immune drug (IL-2) could slow the progression of ALS by boosting helpful immune cells that may calm inflammation in the nervous system. It involved 304 newly diagnosed ALS patients who received either the drug or a placebo for 18 months. The main goal was to see if this approach could improve survival and slow functional decline.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM - Hôpital de la Timone
Marseille, 13385, France
-
APHP - Groupe Hospitalier Pitié-Salpetrière
Paris, 75651, France
-
CENTRE HOSPITALIER DE SAINT BRIEUC - Hôpital Yves Le Foll
Saint-Brieuc, 22027, France
-
CHRU de Lille - Hôpital Roger Salengro
Lille, 59037, France
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
-
CHRU de Tours - Hôpital Bretonneau
Tours, 37044, France
-
CHU de Limoges - Hôpital Dupuytren
Limoges, 87042, France
-
CHU de Nice - Hôpital Pasteur
Nice, 06002, France
-
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, 67098, France
-
Centre for Neuromuscular Diseases - National Hospital of Neurology
London, WC1N 3BG, United Kingdom
-
HCL - Hôpital Neurologique P. Wertheimer
Lyon, 69677, France
-
Institute of Neurological Sciences, Queen Elizabeth University Hospital
Glasgow, G514TF, United Kingdom
-
King's MND Care and Research Centre
London, SE5 8AF, United Kingdom
-
North-East London and Essex MND Regional Care Centre
London, E1 4NS, United Kingdom
-
Salford Royal NHS Foundation Trust, Neurology Dept
Manchester, M6 8HD, United Kingdom
-
Sheffield Care and Research Centre
Sheffield, S10 2JF, United Kingdom
-
Trafford Centre for Biomedical Research
Brighton, BN1 9RY, United Kingdom
Conditions
Explore the condition pages connected to this study.